Tranquis Therapeutics is developing small molecule drugs that reprogram dysfunctional immune cells to restore mitochondrial and lysosomal function, targeting neurodegenerative and aging-related diseases. Their therapies aim to improve cellular homeostasis, potentially transforming the treatment landscape for a range of central nervous system and non-central nervous system conditions.
Funding
$32M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurodegenerative and aging-related diseases are associated with dysfunctional immune cells that have impaired mitochondrial and lysosomal function. This cellular dysfunction contributes to disease progression and limits the effectiveness of existing treatments.
Solution
Tranquis Therapeutics is developing small molecule drugs designed to reprogram dysfunctional immune cells and restore normal mitochondrial and lysosomal function. These therapies aim to re-establish cellular homeostasis, addressing the underlying mechanisms of neurodegenerative and aging-related diseases. By targeting the energy metabolism of dysfunctional immune cells, Tranquis Therapeutics seeks to modify disease progression and improve patient outcomes across a range of central nervous system (CNS) and non-CNS indications. Their therapeutic candidates act as master regulators of mitochondrial and lysosomal function, offering a novel approach to managing these complex conditions.
Target Audience
The primary target audience includes patients suffering from neurodegenerative and aging-related diseases, as well as healthcare providers seeking innovative treatments for these conditions.
Features
- Small molecule drugs designed to reprogram dysfunctional immune cells.
- Therapies target and restore normal mitochondrial function.
- Therapies target and restore normal lysosomal function.
- Aims to re-establish cellular homeostasis.
- Potential application across a range of CNS and non-CNS indications.